A new study helps explain the role of genetic variation in shaping gene regulation in the Indonesian archipelago, one of the most diverse regions in the world. “This study is the only study of splicing from Southeast Asian populations. There is basically no data from this part of the world,” study author Irene Gallego Romero told BioWorld. For drug discovery, most of the people that have historically participated in clinical trials are of European ancestry, and scientists are just beginning to study African populations to better understand genetic differences in these populations, said Romero, a population geneticist and biological anthropologist at the University of Melbourne. Read More
In recent years, immune checkpoint inhibitors have had great success in the treatment of advanced cancers, but often, they are only effective in a minority of patients. Researchers from Weill Cornell Medicine have discovered that the activation of the pentose phosphate pathway (PPP) in combination with standard immune checkpoint inhibitors resulted in enhanced antitumor efficacy both in vitro and in vivo. Read More
Seraxis Inc. has obtained IND clearance from the FDA for a phase I/II study of its novel islet replacement therapy SR-02 for type 1 diabetes. SR-02 is comprised of allogeneic pancreatic endocrine cell clusters that, when implanted to the omentum, form a functional endocrine pancreas outside of the native pancreas. Read More
Myasthenia gravis (MG) is an antibody-mediated chronic neuromuscular disorder leading to fluctuating weakness and early muscle fatigue, with limited treatment options available. In MG, such as other autoimmune diseases, the main pathogenic autoantibody involved is the immunoglobulin G (IgG) isotype. Read More
Shandong New Time Pharmaceutical Co. Ltd. has disclosed compounds acting as Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases. Read More
Insilico Medicine Inc. has synthesized fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer. Read More
In a recent presentation, researchers from the Medical University of Lodz have aimed to investigate the therapeutic potential of simultaneously targeting axin and cannabinoid receptors (CBs) with KYA-1797K and WIN-55212-2 in colorectal cancer (CRC) cell lines SW480 and Caco-2. Read More
The reticulon 4 (Nogo) family, which is located in the endoplasmic reticulum, consists of several members including Nogo-A, Nogo-B and Nogo-C. Since previous studies have linked Nogo-B to multiple metabolic processes, researchers from University of Science and Technology of China (USTC) and affiliated organizations investigated the role of Nogo-B in cholesterol metabolism and related metabolic diseases. Read More
Isomab Ltd. has nominated ISM-001 as a development candidate for peripheral arterial disease. ISM-001 is a potential first-in-class therapeutic antibody designed to neutralize VEGF-A165b, the anti-angiogenic VEGF-A splice isoform that acts as a brake on development of new blood vessels leading to chronic limb threatening ischemia. Read More
Incyte Corp. has identified tyrosine-protein kinase JAK2 (V617F mutant) inhibitors reported to be useful for the treatment of cancer, hypereosinophilic syndrome, systemic mastocytosis and essential thrombocythemia, among others. Read More
Recent decades have brought advances in pharmacological therapies for treating inflammatory bowel disease (IBD), but their sustained efficacy is still not enough, and developing novel therapies is an unmet medical need for this condition. Read More
Ventus Therapeutics US Inc. has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, metabolic diseases, autoimmune diseases, and liver, renal, respiratory, cardiovascular and inflammatory disorders, among others. Read More
Molecure SA has signed an exclusive licensing agreement with Ocean Biomedical Inc. for the development and commercialization of a selective YKL-40 inhibitor program, including the lead molecule OAT-3912. Read More
Atavistik Bio Inc. has nominated an orally bioavailable selective allosteric AKT1 E17K inhibitor, ATV-1601, as a development candidate for AKT1 E17K-driven cancers. Read More
Genetic Intelligence Inc. has described compounds acting as IL-2 expression or activity modulators reported to be useful for the treatment of cancer, infections, autoimmune diseases and inflammatory disorders. Read More
